Tags

Type your tag names separated by a space and hit enter

Quality assurance in melanoma care: guideline-based quality indicators for melanoma - implementation, evaluation and update process.
J Dtsch Dermatol Ges. 2020 Jun 23 [Online ahead of print]JD

Abstract

BACKGROUND

In 2018, an update of the German evidence-based (S3) guidelines "Diagnosis, Therapy and Follow-up of Melanoma" first issued in 2013 was published under the auspices of the German Guideline Program in Oncology. The update also included a revision of existing guideline-based quality indicators (QIs).

PATIENTS AND METHODS

Using a standardized multi-step process, the guideline-derived QIs were revised by a multidisciplinary, interprofessional working group based on the strong (level A) recommendations contained in the guideline update as well as on a systematic literature search for international indicators and on the outcomes of existing QIs as reported by certified German skin cancer centers.

RESULTS

Based on the original set of twelve guideline-based QIs agreed upon in 2013, the working group developed an updated set containing nine indicators. Four QIs were kept unchanged; two were modified; two were removed; and three new QIs were added. Unlike 2013, the working group was now able to incorporate the outcomes of QIs previously implemented at the various skin cancer centers.

CONCLUSIONS

Close cooperation between guideline group and certification commission allows for the implementation of guideline-based QIs in cancer care. Measured outcomes form the basis for updating both the guidelines and the QI development process. They provide information about the care of cancer patients in a real-world setting as well as on guideline adherence and the feasibility of QIs themselves. This is a dynamic process that can be described in a transparent manner and that requires regular updating.

Authors+Show Affiliations

German Cancer Society, Berlin, Germany.Department of Dermatology, University Medical Center, Tübingen, Germany.German Cancer Society, Berlin, Germany.German Cancer Society, Berlin, Germany.German Cancer Society, Berlin, Germany.German Cancer Society, Berlin, Germany.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32578392

Citation

Follmann, Markus, et al. "Quality Assurance in Melanoma Care: Guideline-based Quality Indicators for Melanoma - Implementation, Evaluation and Update Process." Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020.
Follmann M, Eigentler T, Adam H, et al. Quality assurance in melanoma care: guideline-based quality indicators for melanoma - implementation, evaluation and update process. J Dtsch Dermatol Ges. 2020.
Follmann, M., Eigentler, T., Adam, H., Wenzel, G., Langer, T., & Wesselmann, S. (2020). Quality assurance in melanoma care: guideline-based quality indicators for melanoma - implementation, evaluation and update process. Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. https://doi.org/10.1111/ddg.14149
Follmann M, et al. Quality Assurance in Melanoma Care: Guideline-based Quality Indicators for Melanoma - Implementation, Evaluation and Update Process. J Dtsch Dermatol Ges. 2020 Jun 23; PubMed PMID: 32578392.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quality assurance in melanoma care: guideline-based quality indicators for melanoma - implementation, evaluation and update process. AU - Follmann,Markus, AU - Eigentler,Thomas, AU - Adam,Henning, AU - Wenzel,Gregor, AU - Langer,Thomas, AU - Wesselmann,Simone, Y1 - 2020/06/23/ PY - 2019/09/18/received PY - 2020/01/29/accepted PY - 2020/6/25/entrez JF - Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG JO - J Dtsch Dermatol Ges N2 - BACKGROUND: In 2018, an update of the German evidence-based (S3) guidelines "Diagnosis, Therapy and Follow-up of Melanoma" first issued in 2013 was published under the auspices of the German Guideline Program in Oncology. The update also included a revision of existing guideline-based quality indicators (QIs). PATIENTS AND METHODS: Using a standardized multi-step process, the guideline-derived QIs were revised by a multidisciplinary, interprofessional working group based on the strong (level A) recommendations contained in the guideline update as well as on a systematic literature search for international indicators and on the outcomes of existing QIs as reported by certified German skin cancer centers. RESULTS: Based on the original set of twelve guideline-based QIs agreed upon in 2013, the working group developed an updated set containing nine indicators. Four QIs were kept unchanged; two were modified; two were removed; and three new QIs were added. Unlike 2013, the working group was now able to incorporate the outcomes of QIs previously implemented at the various skin cancer centers. CONCLUSIONS: Close cooperation between guideline group and certification commission allows for the implementation of guideline-based QIs in cancer care. Measured outcomes form the basis for updating both the guidelines and the QI development process. They provide information about the care of cancer patients in a real-world setting as well as on guideline adherence and the feasibility of QIs themselves. This is a dynamic process that can be described in a transparent manner and that requires regular updating. SN - 1610-0387 UR - https://www.unboundmedicine.com/medline/citation/32578392/Quality_assurance_in_melanoma_care:_guideline_based_quality_indicators_for_melanoma___implementation_evaluation_and_update_process_ L2 - https://doi.org/10.1111/ddg.14149 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.